Good evening. This snapshot of stories and roundup is recommended just for you, based on your interests and reading history. | | | | The Food and Drug Administration will allow more patients to have early access to a pancreatic cancer drug as the treatment awaits official approval from the agency. (Maansi Srivastava/For The Washington Post) | | | | | | |  What to know The FDA authorized expanded access for Revolution Medicines' pancreatic cancer drug daraxonrasib, allowing wider patient use during regulatory review. The drug has doubled survival time in trials, addressing the urgent need for effective treatments. Approval could come this year. Summary is AI-generated, newsroom-reviewed. | | | Column Judith Martin, Nicholas Martin and Jacobina Martin | | | | Opinion Letters to the Editor | | | | How was today's newsletter? | | | | | | | | |
Have a question? Ask the Post AI to learn more 
